Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002109 · ClinicalTrials.gov registry record · Phase 3
Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy
A Phase 3 study, sponsored by Immunobiology Research Institute.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00002109: Completed Phase 3 study, sponsored by Immunobiology Research Institute.
NCT00002109 is a Phase 3 study that has completed, run by Immunobiology Research Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002109, a Phase 3 study, has completed, sponsored by Immunobiology Research Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
To confirm results from a previous study in which the combination of thymopentin plus zidovudine ( AZT ), an antiretroviral agent, slowed disease progression in HIV-infected asymptomatic patients. To evaluate the efficacy and safety of thymopentin in HIV-infected asymptomatic patients receiving either monotherapy with AZT, didanosine ( ddI ), or stavudine ( d4T ), or combination antiretroviral therapy with AZT / ddI or AZT / zalcitabine ( ddC ).
Interventions
- DRUG Zidovudine
- DRUG Stavudine
- DRUG Didanosine
- DRUG Zalcitabine
- DRUG Thymopentin
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002109
The ClinicalTrials.gov registry entry for NCT00002109 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Immunobiology Research Institute, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Zidovudine is the first listed.
NCT00002109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002109 about?
NCT00002109 is a clinical study titled "Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy". To confirm results from a previous study in which the combination of thymopentin plus zidovudine ( AZT ), an antiretroviral agent, slowed disease progression in HIV-infected asymptomatic patients. To evaluate the efficacy and safety of thymopentin in HIV-infected asymptomatic patients receiving eith...
What is the current status of trial NCT00002109?
This trial is currently completed. It is a Phase 3 study.
What interventions are being tested in trial NCT00002109?
The interventions under investigation include: Zidovudine (DRUG), Stavudine (DRUG), Didanosine (DRUG), Zalcitabine (DRUG), Thymopentin (DRUG).
Who is sponsoring clinical trial NCT00002109?
This trial is sponsored by Immunobiology Research Institute, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.